Admin_Adham
Jump to Key Points Vaginal microbiomes have become a focus for health influencers, with probiotics increasingly being promoted as a way to improve vaginal health, reduce unpleasant odors, and prevent bacterial vaginosis (BV) and yeast infections. However, evidence supporting these claims is limited to specific probiotic preparations and clinical settings and cannot be generalized to products marketed online.
What Evidence Shows
Some evidence supports the use of specific probiotics to reduce the risk for recurrent BV, particularly when used after antibiotic treatment.
A 2022 systematic review and meta-analysis of 18 studies involving 1651 patients found that probiotics, particularly when combined with antibiotics, reduced the risk for recurrent BV. Another systematic review reported similar results.
Evidence from a randomized controlled trial of Lactin-V showed that a 12-week course of Lactin-V, a preparation containing a specific strain of Lactobacillus crispatus, administered after metronidazole treatment, significantly reduced BV recurrence compared with placebo.
- Specific Lactobacillus probiotics may ↓ recurrent BV, mainly post-antibiotics.
- Lactin-V after metronidazole significantly reduced BV recurrence vs placebo.
- Findings are strain-, dose-, route-, duration-, and population-specific.
- Vulvovaginal candidiasis data are inconsistent; fluconazole > probiotics.
- Self-diagnosis from vaginal wellness trends may delay proper evaluation/treatment.
These findings should not be generalized to all products marketed as “vaginal health probiotics.” Strain, dose, route of administration, treatment duration, and patient population can influence treatment outcomes.
Evidence for the use of probiotics in vulvovaginal candidiasis is inconsistent.
A 2023 study reported the beneficial effects of probiotics in vulvovaginal candidiasis. However, a subsequent review questioned the strength of the evidence. Probiotics also do not replace the established antifungal treatments. Fluconazole is more effective than probiotics for the treatment of vulvovaginal candidiasis.
A greater concern regarding vaginal wellness is the potential for self-diagnosis. Patients who attribute itching, unpleasant odor, or vaginal discharge to an imbalance in the vaginal microbiome may turn to products promoted by influencers instead of seeking medical evaluation. This can delay the appropriate diagnosis and treatment of vaginal infections and other conditions.
There is some scientific basis for claims about vaginal wellness trends, but the evidence is limited and should not be extrapolated to every commercial product.
Probiotics containing specific Lactobacillus strains reduce the risk for recurrent BV, particularly in specific treatment settings. However, evidence of their role in vulvovaginal candidiasis remains inconclusive.
Interpretations of clinical data regarding vaginal wellness are largely dependent on variables such as specific strain, formulation, dose, route of administration, and patient characteristics. A probiotic product marketed for “vaginal health” cannot automatically be assumed to provide the clinical benefits demonstrated in scientific trials.
The greatest risk associated with vaginal wellness trends is the self-diagnosis they encourage, which can delay or prevent the proper treatment of actual medical conditions.
This story was translated from Univadis Germany, part of the Medscape Professional Network.
